Merus Labs announces EU promotion, distribution agreements for Emselex/Enablex

Merus Labs International announced that through its wholly owned subsidiaries, Merus Labs B.V and Merus Labs Luxco S.a R.L., it has entered into promotion and distribution agreements with selected partners in certain European countries for the company's Emselex/Enablex product. Emselex/Enablex is a branded prescription medicine in extended release tablet form which is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.